Sugi Predict

Sugi Predict / Compounds / SCHEMBL358552

SCHEMBL358552

SCHEMBL358552

CC(C)(C#N)c1ccc(N)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ JAK2 O60674 2/20 0.36
▸ ROCK2 O75116 2/20 0.36
▸ PRKCA P17252 2/20 0.36
▸ PRKCQ Q04759 2/20 0.36
▸ PRKCD Q05655 2/20 0.36
▸ ROCK1 Q13464 2/20 0.36
▸ PRKACA P17612 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA4 P22748 1/20 0.33
▸ CA6 P23280 1/20 0.33
▸ CA5A P35218 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1478398 0.78 CHRNA7 (0.46) CHRNA7KDM4ERAB9AJAK2ROCK2
SCHEMBL31718069 0.78 CHRNA7 (0.46) CHRNA7KDM4ERAB9AJAK2ROCK2
SCHEMBL30004124 0.77 KDM4E (0.46) KDM4EPOLBRAB9ACA12CA1
SCHEMBL2367892 0.77 KDM4E (0.46) KDM4EPOLBRAB9ACA12CA1
SCHEMBL1403854 0.77 CHRNA7 (0.44) CHRNA7KDM4EJAK2ROCK2PRKCA
SCHEMBL21227047 0.77 CHRNA7 (0.44) CHRNA7JAK2ROCK2PRKCAPRKCQ
SCHEMBL20304972 0.77 CHRNA7 (0.44) CHRNA7KDM4EPIK3CAMTOR
SCHEMBL4573186 0.77 CHRNA7 (0.44) CHRNA7JAK2ROCK2PRKCAPRKCQ
SCHEMBL31275885 0.75 CHRNA7 (0.44) CHRNA7JAK2ROCK2PRKCAPRKCQ
SCHEMBL28608713 0.75 CHRNA7 (0.44) CHRNA7JAK2ROCK2PRKCAPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117800964-A PI3K/m-TOR inhibitor and application thereof 四川大学 2024-04-02 — — CN disclosed
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2024-02-08 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807644-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
CN-116710430-A Methods and compounds for restoring mutant p53 function 皮姆维制药公司 2023-09-05 — — CN disclosed
EP-4149459-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-03-22 — — EP disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 — — US disclosed
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-01-05 — — US disclosed
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2022-07-07 — — US disclosed
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2013-07-25 — — US disclosed
EP-2616468-A1 FUSED HETEROARYLS AND THEIR USES Hutchison Medipharma Limited (CN) 2013-07-24 — — EP disclosed
CN-103124731-A Fused heteroaryl compounds and uses thereof HUTCHISON MEDIPHARMA LTD 2013-05-29 — — CN disclosed
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 — — EP disclosed
CN-103108873-A Substituted imidazoquinoline derivatives as kinase inhibitors PIRAMAL LIFE SCIENCES LTD 2013-05-15 — — CN disclosed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 — — US disclosed
WO-2012077031-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-06-14 — — WO disclosed
WO-2012034526-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2012-03-22 — — WO disclosed
WO-2012034526-A1 FUSED HETEROARYLS AND THEIR USES HUTCHISON MEDIPHARMA LIMITED (CN) 2012-03-22 — — WO disclosed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS CDK2, CDK4, MAP3K1 CHRNA7 3441/4885KDM4E 600/4885POLB 2112/4885
US-20220213062-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS CHRNA7 4572/4885KDM4E 2994/4885POLB 70/4885
US-20230002403-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS CHRNA7 4482/4885KDM4E 3311/4885POLB 76/4885
US-11807644-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS CHRNA7 4482/4885KDM4E 3311/4885POLB 76/4885
US-20130190307-A1 FUSED HETEROARYLS AND THEIR USES FARS2, TIAL1, DHFR CHRNA7 2923/4885KDM4E 4268/4885POLB 2322/4885
US-20240043436-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS CHRNA7 4482/4885KDM4E 3311/4885POLB 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.